Wednesday, July 8, 2026

biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT

Adaptive Biotechnologies

Adaptive Biotechnologies clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
Status
Public
HQ
1165 Eastlake Ave E, Seattle, Washington 98109, US
Founded
2009
Employees
659
Programs
19
Drugs
23
Patents
12
Intelligence · Clinical Programs

Adaptive Biotechnologies projects

3 ClinicalTrials.gov programs sponsored by Adaptive Biotechnologies.

Adaptive Biotechnologies has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial
  2. GCAR-7213

    Adaptive Biotechnologies Corp

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial
  3. Temozolomide

    Adaptive Biotechnologies Corp

    Glioblastoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Adaptive Biotechnologies have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.